Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Return on Sales (2016 - 2025)

Historic Return on Sales for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to 0.11%.

  • Heron Therapeutics' Return on Sales rose 300.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.1% for FY2024, which is 7800.0% up from last year.
  • Heron Therapeutics' Return on Sales amounted to 0.11% in Q3 2025, which was up 300.0% from 0.04% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Return on Sales ranged from a high of 0.1% in Q4 2024 and a low of 2.69% during Q2 2021
  • For the 5-year period, Heron Therapeutics' Return on Sales averaged around 1.1%, with its median value being 0.79% (2023).
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by -5300bps in 2021, then soared by 19100bps in 2022.
  • Heron Therapeutics' Return on Sales (Quarter) stood at 2.59% in 2021, then soared by 74bps to 0.68% in 2022, then skyrocketed by 56bps to 0.3% in 2023, then soared by 134bps to 0.1% in 2024, then plummeted by -205bps to 0.11% in 2025.
  • Its last three reported values are 0.11% in Q3 2025, 0.04% for Q2 2025, and 0.08% during Q1 2025.